Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes

Abstract

Drug-induced cardiotoxicity and hepatotoxicity are major causes of drug attrition. To decrease late-stage drug attrition, pharmaceutical and biotechnology industries need to establish biologically relevant models that use phenotypic screening to detect drug-induced toxicity in vitro. In this study, we sought to rapidly detect patterns of cardiotoxicity using high-content image analysis with deep learning and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). We screened a library of 1280 bioactive compounds and identified those with potential cardiotoxic liabilities in iPSC-CMs using a single-parameter score based on deep learning. Compounds demonstrating cardiotoxicity in iPSC-CMs included DNA intercalators, ion channel blockers, epidermal growth factor receptor, cyclin-dependent kinase, and multi-kinase inhibitors. We also screened a diverse library of molecules with unknown targets and identified chemical frameworks that show cardiotoxic signal in iPSC-CMs. By using this screening approach during target discovery and lead optimization, we can de-risk early-stage drug discovery. We show that the broad applicability of combining deep learning with iPSC technology is an effective way to interrogate cellular phenotypes and identify drugs that may protect against diseased phenotypes and deleterious mutations.

Data availability

Our RNA-Seq data has been deposited on the Gene Expression Omnibus (GEO) database. GEO Submission (GSE172181):https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172181

The following data sets were generated

Article and author information

Author details

  1. Francis Grafton

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Francis Grafton, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  2. Jaclyn Ho

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Jaclyn Ho, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  3. Sara Ranjbarvaziri

    Pediatrics (Cardiology),, Stanford University, Palo Alto, United States
    Competing interests
    No competing interests declared.
  4. Farshad Farshidfar

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Farshad Farshidfar, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  5. Anastasiia Budan

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Anastasiia Budan, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  6. Stephanie Steltzer

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Stephanie Steltzer, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  7. Mahnaz Maddah

    -, Dana Solutions, Palo Alto, United States
    Competing interests
    Mahnaz Maddah, is affiliated with Dana Solutions. The author has no other competing interests to declare..
  8. Kevin E Loewke

    -, Dana Solutions, Palo Alto, United States
    Competing interests
    Kevin E Loewke, is affiliated with Dana Solutions. The author has no other competing interests to declare..
  9. Kristina Green

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Kristina Green, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  10. Snahel Patel

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Snahel Patel, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  11. Tim Hoey

    Drug Discovery, Tenaya Therapeutics, South San Francisco, United States
    Competing interests
    Tim Hoey, is an employee of Tenaya Therapeutics and has stock holdings in the company..
  12. Mohammad Ali Mandegar

    Tenaya Therapeutics, Tenaya Therapeutics, South San Francisco, United States
    For correspondence
    mandegar@tenayathera.com
    Competing interests
    Mohammad Ali Mandegar, is an employee of Tenaya Therapeutics and has stock holdings in the company..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5323-7891

Funding

No external funding was received for this work

Copyright

© 2021, Grafton et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,660
    views
  • 656
    downloads
  • 43
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Francis Grafton
  2. Jaclyn Ho
  3. Sara Ranjbarvaziri
  4. Farshad Farshidfar
  5. Anastasiia Budan
  6. Stephanie Steltzer
  7. Mahnaz Maddah
  8. Kevin E Loewke
  9. Kristina Green
  10. Snahel Patel
  11. Tim Hoey
  12. Mohammad Ali Mandegar
(2021)
Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes
eLife 10:e68714.
https://doi.org/10.7554/eLife.68714

Share this article

https://doi.org/10.7554/eLife.68714

Further reading

    1. Stem Cells and Regenerative Medicine
    Sujeethkumar Prithiviraj, Alejandro Garcia Garcia ... Paul E Bourgine
    Research Article

    Tissue engineering strategies predominantly rely on the production of living substitutes, whereby implanted cells actively participate in the regenerative process. Beyond cost and delayed graft availability, the patient-specific performance of engineered tissues poses serious concerns on their clinical translation ability. A more exciting paradigm consists in exploiting cell-laid, engineered extracellular matrices (eECMs), which can be used as off-the-shelf materials. Here, the regenerative capacity solely relies on the preservation of the eECM structure and embedded signals to instruct an endogenous repair. We recently described the possibility to exploit custom human stem cell lines for eECM manufacturing. In addition to the conferred standardization, the availability of such cell lines opened avenues for the design of tailored eECMs by applying dedicated genetic tools. In this study, we demonstrated the exploitation of CRISPR/Cas9 as a high precision system for editing the composition and function of eECMs. Human mesenchymal stromal/stem cell (hMSC) lines were modified to knock out vascular endothelial growth factor (VEGF) and Runt-related transcription factor 2 (RUNX2) and assessed for their capacity to generate osteoinductive cartilage matrices. We report the successful editing of hMSCs, subsequently leading to targeted VEGF and RUNX2-knockout cartilage eECMs. Despite the absence of VEGF, eECMs retained full capacity to instruct ectopic endochondral ossification. Conversely, RUNX2-edited eECMs exhibited impaired hypertrophy, reduced ectopic ossification, and superior cartilage repair in a rat osteochondral defect. In summary, our approach can be harnessed to identify the necessary eECM factors driving endogenous repair. Our work paves the road toward the compositional eECMs editing and their exploitation in broad regenerative contexts.

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Joshua G Medina-Feliciano, Griselle Valentín-Tirado ... José E Garcia-Arraras
    Research Article

    In holothurians, the regenerative process following evisceration involves the development of a ‘rudiment’ or ‘anlage’ at the injured end of the mesentery. This regenerating anlage plays a pivotal role in the formation of a new intestine. Despite its significance, our understanding of the molecular characteristics inherent to the constituent cells of this structure has remained limited. To address this gap, we employed state-of-the-art scRNA-seq and hybridization chain reaction fluorescent in situ hybridization analyses to discern the distinct cellular populations associated with the regeneration anlage. Through this approach, we successfully identified 13 distinct cell clusters. Among these, two clusters exhibit characteristics consistent with putative mesenchymal cells, while another four show features akin to coelomocyte cell populations. The remaining seven cell clusters collectively form a large group encompassing the coelomic epithelium of the regenerating anlage and mesentery. Within this large group of clusters, we recognized previously documented cell populations such as muscle precursors, neuroepithelial cells, and actively proliferating cells. Strikingly, our analysis provides data for identifying at least four other cellular populations that we define as the precursor cells of the growing anlage. Consequently, our findings strengthen the hypothesis that the coelomic epithelium of the anlage is a pluripotent tissue that gives rise to diverse cell types of the regenerating intestinal organ. Moreover, our results provide the initial view into the transcriptomic analysis of cell populations responsible for the amazing regenerative capabilities of echinoderms.